These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16430799)

  • 41. The use of aprotinin in Norway.
    Bjella L; Greiff G; Pleym H; Stenseth R; Wahba A
    Acta Anaesthesiol Scand; 2007 Feb; 51(2):261; author reply 261. PubMed ID: 17261150
    [No Abstract]   [Full Text] [Related]  

  • 42. Aprotinin and renal dysfunction.
    Bosman M; Royston D
    Expert Opin Drug Saf; 2008 Nov; 7(6):663-77. PubMed ID: 18983214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aprotinin in cardiac surgery.
    Sodha NR; Boodhwani M; Bianchi C; Ramlawi B; Sellke FW
    Expert Rev Cardiovasc Ther; 2006 Mar; 4(2):151-60. PubMed ID: 16509811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.
    Mahesh B; Yim B; Robson D; Pillai R; Ratnatunga C; Pigott D
    Eur J Cardiothorac Surg; 2008 Mar; 33(3):370-6. PubMed ID: 18243724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of aprotinin on renal function after liver transplantation: an analysis of 1,043 patients.
    Warnaar N; Mallett SV; de Boer MT; Rolando N; Burroughs AK; Nijsten MW; Slooff MJ; Rolles K; Porte RJ
    Am J Transplant; 2007 Oct; 7(10):2378-87. PubMed ID: 17711552
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activated clotting time measurements and aprotinin studies.
    Abramson DC; Pivalizza EG; Gottschalk LI
    Circulation; 1996 Oct; 94(7):1791-2. PubMed ID: 8840885
    [No Abstract]   [Full Text] [Related]  

  • 47. Con: aprotinin should not be used in patients undergoing hypothermic circulatory arrest.
    Gravlee GP
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):126-8. PubMed ID: 11254855
    [No Abstract]   [Full Text] [Related]  

  • 48. Long-term mortality associated with aprotinin following coronary artery bypass graft surgery.
    Scharnetzky E; Schill W; Garbe E
    JAMA; 2007 Jun; 297(22):2475; author reply 2477. PubMed ID: 17565076
    [No Abstract]   [Full Text] [Related]  

  • 49. A comparison before and after aprotinin was suspended in cardiac surgery: different results in the real world from a single cardiac center in China.
    Wang X; Zheng Z; Ao H; Zhang S; Wang Y; Zhang H; Li L; Hu S
    J Thorac Cardiovasc Surg; 2009 Oct; 138(4):897-903. PubMed ID: 19660368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study.
    Ngaage DL; Cale AR; Cowen ME; Griffin S; Guvendik L
    Ann Thorac Surg; 2008 Oct; 86(4):1195-202. PubMed ID: 18805159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aprotinin use during cardiac surgery: a new or continuing controversy?
    Hogue CW; London MJ
    Anesth Analg; 2006 Nov; 103(5):1067-70. PubMed ID: 17056933
    [No Abstract]   [Full Text] [Related]  

  • 52. ICVTS on-line discussion A Plateletpheresis or aprotinin, which is the key element?
    Kan CD
    Interact Cardiovasc Thorac Surg; 2007 Oct; 6(5):622; discussion 622. PubMed ID: 17884856
    [No Abstract]   [Full Text] [Related]  

  • 53. Magnetic resonance imaging registration and quantitation of the brain before and after coronary artery bypass graft surgery.
    Kohn A
    Ann Thorac Surg; 2002 Jan; 73(1):S363-5. PubMed ID: 11834072
    [No Abstract]   [Full Text] [Related]  

  • 54. Novel antithrombotic agents and the risk of bleeding.
    van der Linden J
    Transfusion; 2008 Mar; 48(1 Suppl):47S-50S. PubMed ID: 18302582
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trasylol Pediatric Investigational Meeting. Introduction.
    Greeley WJ
    Ann Thorac Surg; 1998 Jun; 65(6 Suppl):S29-30. PubMed ID: 9647134
    [No Abstract]   [Full Text] [Related]  

  • 56. Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.
    Lindvall G; Sartipy U; Ivert T; van der Linden J
    Ann Thorac Surg; 2008 Jul; 86(1):13-9. PubMed ID: 18573391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High transoxygenator pressure gradient in a patient with polycythemia vera.
    Fieldwalker MA; Jackson SC; Seal D
    J Cardiothorac Vasc Anesth; 2010 Feb; 24(1):104-8. PubMed ID: 19362496
    [No Abstract]   [Full Text] [Related]  

  • 59. Aprotinin: 1 year on.
    Dietrich W
    Curr Opin Anaesthesiol; 2009 Feb; 22(1):121-7. PubMed ID: 19295302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of aprotinin for patients undergoing coronary artery bypass graft procedures.
    Whitener RT; Doyal VL
    AORN J; 1996 Jan; 63(1):229-34. PubMed ID: 9131111
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.